Rationale Endogenous γ-aminobutyric acid A receptor (GABA A R)-active neurosteroids (e.g., allopregnanolone) regulate central nervous system excitability and many physiological functions, so fluctuations are implicated in several neuropsychiatric disorders. Pertinently, evidence supports an inverse relationship between endogenous GABA A R-active neurosteroid levels and behavioral changes in excitability during ethanol withdrawal (WD). Objectives The present studies determined mouse genotype differences in ten neurosteroid levels in plasma, cortex, and hippocampus over the time course of ethanol WD in the WD Seizure-Prone (WSP) and WD Seizure-Resistant (WSR) selected lines and in the DBA/2J (DBA) inbred strain. Methods Gas chromatography-mass spectrometry was utilized to simultaneously quantify neurosteroid levels from control-treated male WSP-1, WSR-1, and DBA mice and during 8 and 48 h of WD.
Introduction
Endogenous neurosteroids that rapidly enhance γ-aminobutyric acid A receptor (GABA A R)-mediated inhibition (e.g., Belelli and Lambert 2005; Carver and Reddy 2013; Paul and Purdy 1992) are formed by the 5α-/5β-and then 3α-reduction of the parent steroids progesterone, deoxycorticosterone (DOC), testosterone, and dehydroepiandrosterone (DHEA; e.g., Finn et al. 2004; Porcu et al. 2009 Porcu et al. , 2016 Snelling et al. 2014) . The progesterone metabolites allopregnanolone (ALLO; 3α,5α-THP or tetrahydroprogesterone) and pregnanolone (3α,5β-THP) and Electronic supplementary material The online version of this article (doi:10.1007/s00213-017-4671-0) contains supplementary material, which is available to authorized users.
the DOC metabolite tetrahydrodeoxycorticosterone (3α,5α-THDOC) are the three most potent neurosteroids characterized to date, as they enhance GABA A R-mediated inhibition with nanomolar potencies, directly activate GABA A Rs with micromolar potencies, and exert effects on other ligand gated ion channels with micromolar potencies (Belelli and Lambert 2005; Belelli et al. 1990; Carver and Reddy 2013; Paul and Purdy 1992; Purdy et al. 1990; Rupprecht and Holsboer 1999; Veleiro and Burton 2009) . The testosterone metabolite 3α,5α-androstanediol and the DHEA metabolite 3α,5α-androsterone potentiate GABA A Rs but with lower potency than ALLO and 3α,5α-THDOC (Carver and Reddy 2013; Porcu et al. 2016) . Importantly, all steroidogenic enzymes are localized in the nervous system and in peripheral steroidogenic tissues (Do Rego et al. 2009; Mellon and Vaudry 2001) , indicating that neurosteroid levels in the brain reflect a combination of compounds produced there de novo and from metabolism of circulating precursors. Because endogenous levels of ALLO and 3α,5α-THDOC fluctuate in the 10-100 nM range that enhance GABA A R inhibition (Barbaccia et al. 2001; Belelli and Lambert 2005; Carver and Reddy 2013; Finn et al. 2004; Paul and Purdy 1992) , these neurosteroids can regulate central nervous system (CNS) excitability. Accumulating evidence suggests that dysregulation in neurosteroid synthesis contributes to symptoms in several neuropsychiatric and neurodegenerative diseases and that targeting neurosteroid biosynthesis may be an effective treatment strategy (Porcu et al. 2016) .
Alcohol (ethanol) withdrawal (WD) is one important dimension of genetic risk for dependence (Kendler et al. 2012) , and WD-induced seizure activity increases with successive WD in both humans and animals (Duka et al. 2004) . Repeated WDs are associated with deficits in cognitive function and emotional processing (e.g., Stephens and Duka 2008; Sullivan et al. 2000) and are suggested to contribute to continued drinking (Ripley and Stephens 2011) , which underscores the importance of examining mechanisms underlying high withdrawal (Heilig et al. 2010) . We and others found that WD is associated with a decrease in GABA A R inhibition mediated by a variety of factors that includes functional changes in GABA A R properties, a reduction in the steroidogenic effect of acute ethanol administration, and a decrease in endogenous ALLO levels (see Finn et al. 2004; Kumar et al. 2009 ). In rodents, monkeys, and humans, WD decreases ALLO levels in plasma and several brain regions (Beattie et al. 2017; Cagetti et al. 2004; Hill et al. 2005; Maldonado-Devincci et al. 2014; Romeo et al. 1996; Snelling et al. 2014; Tanchuck et al. 2009 ). In small cohorts of male and female alcoholics, the decrease in ALLO and 3α,5α-THDOC levels corresponded to an increase in the subjective ratings of anxiety and depression during days 4-5 of WD, versus controls (Hill et al. 2005; Romeo et al. 1996) . In male cynomolgus monkeys that had been consuming ethanol for over 12 months, there was a significant decrease in plasma ALLO levels and in ALLO immunoreactivity in the lateral and basolateral amygdala (only amygdala examined) at 48 h following the last drinking session versus controls (Beattie et al. 2017) . A significant negative correlation between ALLO immunoreactivity in the lateral and basolateral amygdala and average daily ethanol consumption suggested that WD from high ethanol consumption corresponded to lower ALLO immunoreactivity. WD (48 h) from chronic intermittent ethanol (CIE) intragastric exposure significantly decreased hippocampal ALLO levels, which was associated with a significant increase in anxiety and impairment in hippocampal-dependent memory function in male rats (Cagetti et al. 2004) . Collectively, chronic ethanol WD produces a consistent reduction in endogenous ALLO levels that may be associated with increased cellular excitability, high prior ethanol consumption, and increased aversive behavioral effects (e.g., anxiety, depression, convulsive activity, cognitive impairment).
Our laboratory has been using two different genetic models of ethanol WD severity [WD Seizure-Prone (WSP, severe) versus WD Seizure-Resistant (WSR, negligible) selected lines; DBA/2J (DBA, high) versus C57BL/6J (C57, mild) inbred strains] to test the hypothesis that genetic differences in ethanol WD severity were due in part to alterations in the GABA A R modulatory effects of neurosteroids such as ALLO. Both WSP and DBA mice exhibit high WD severity, measured by increased handling-induced convulsions (HICs) and anxiety following 72 h of continuous ethanol vapor or CIE vapor (Crabbe et al. 1985; Crabbe 1998; Finn and Crabbe 1999; Finn et al. 2004; Gorin et al. 2005; Kosobud and Crabbe 1986; McCool and Chappell 2015; Metten and Crabbe 2005; Metten et al. 2010) . Importantly, both WSP and DBA mice exhibited tolerance to ALLO's anticonvulsant effect during peak (8 h) WD (Beckley et al. 2008; Finn et al. 2000 Finn et al. , 2004 Finn et al. , 2006 , and this tolerance in WSP mice also corresponded to a reduction in functional sensitivity of GABA A Rs to ALLO (Finn et al. 2006 ) and reduced anticonvulsant effect of intra-CA1 ALLO (Gililland-Kaufman et al. 2008) . Thus, a reduction in GABA A R sensitivity to neurosteroids may contribute to a severe WD phenotype in genetic animal models of high WD.
While the majority of studies have examined relationships between ALLO and measures of ethanol WD, neurosteroid synthesis is a dynamic process, so disruptions in one or more biosynthetic steps could influence levels of multiple steroids with positive or negative modulatory effects at GABA A Rs. Furthermore, since GABA A Rs and other targets have varying degrees of sensitivity to multiple neurosteroids, the state of GABA A Rs will depend on the relative levels of all neurosteroids working in concert to coordinate the physiological control of CNS excitability. Thus, determining the net effect of ethanol WD on GABA A Rs requires a detailed analysis of multiple neurosteroids simultaneously.
We recently modified a gas chromatography-mass spectrometry (GC-MS) method ) to simultaneously quantify the GABA A R-active 3α,5α-/3α,5β-reduced metabolites of progesterone, DOC, testosterone and DHEA as well as the precursors pregnenolone and DHEA in plasma from control WSP and WSR mice from the first genetic replicate (WSP-1 and WSR-1) and at 8 h WD from 72 h continuous ethanol vapor exposure (Snelling et al. 2014) ; there was no line difference in the WD-induced suppression in plasma DHEA, ALLO, 3α,5α/3α,5β-androstanediol, and 3α,5α-androsterone levels or increase in plasma corticosterone (CORT) levels. While the pattern of changes in steroid levels imply that ethanol WD is exerting independent effects at several steps of the steroidogenic pathway in plasma (discussed in Snelling et al. 2014) , it is not known if similar results would be observed in discrete brain regions. So, cortex and hippocampus were examined in the present studies, based on evidence that basal neurosteroid levels in plasma do not fully reflect levels in cortex and hippocampus (Caruso et al. 2013) and that divergent changes in ALLO immunoreactivity were observed during WD in mPFC and CA3 (Maldonado-Devincci et al. 2014) . Cortical and hippocampal regions also exhibit increased spike and sharp wave activity in the electroencephalogram (e.g., Veatch and Becker 2002; Veatch and Gonzalez 1996) and increased immediate early gene expression (Vilpoux et al. 2009 ) that was greater in DBA versus C57 mice (Chen et al. 2009 ) during WD, highlighting the importance of these brain regions in WD circuitry. Thus, one purpose of the present experiments was to use GC-MS to simultaneously quantify a panel of 10 neurosteroids in plasma, cortex, and hippocampus in control-treated male WSP-1 and WSR-1 mice and over the time course of WD that corresponded to enhanced convulsive activity in WSP mice (i.e., 8 and 48 h; Finn et al. 2004; Gililland-Kaufman et al. 2008) , and that also corresponded to the acute phase of WD in mice (i.e., 0-48 h in rodents; Heilig et al. 2010) . We predicted that the WDinduced changes in brain neurosteroid levels would differ from the pattern detected in plasma and that there would be a line difference in hippocampal and cortical neurosteroid levels during WD. A second purpose was to conduct similar studies in male DBA mice, and to compare the WD-induced changes in neurosteroid levels across two genetic animal models of high ethanol WD. We predicted that there would be similarities in the pattern of results in DBA and WSP-1 mice, consistent with a genetic influence on the proposed inverse relationship between GABA A R-active neurosteroid levels and ethanol WD severity.
Materials and methods
Animals Drug-naïve male WSP-1 and WSR-1 mice were bred in the Veterinary Medical Unit at the VA Portland Health Care System (VAPORHCS; Portland, OR), were housed two to four per cage with free access to food and water upon weaning, and were acclimated to a 12:12-h light/dark cycle (lights on at 0600). At the time of testing, mice were from selected generation 26 (filial generation 132 for 8 h study and filial generations 130-131 for 48 h study) and were 51-77 days old (8 h study) or 47-101 days old (48 h study). Drugnaïve male DBA mice were purchased from Jackson Laboratories West (Sacramento, CA) at 8 weeks of age, housed four per cage with free access to food and water in the Department of Comparative Medicine at Oregon Health & Science University (OHSU; Portland, OR), and were acclimated to a 12:12-h light/dark cycle (lights on at 0700) for 2 weeks before experimentation. All procedures complied with the National Institute of Health Guidelines for the Care and Use of Laboratory Animals, 8th ed (National Research Council of the National Academies 2011) and were approved by the local Institutional Animal Care and Use Committees at VAPORHCS (WSP and WSR studies) and at OHSU (DBA studies).
Chronic ethanol exposure Mice were exposed to ethanol vapor or air for 72 h by the Dependence Core of the Portland Alcohol Research Center at the VAPORHCS (WSP and WSR studies) or by the Finn laboratory at OHSU (DBA studies), using identical equipment, facilities, and standardized method for inducing ethanol dependence with continuous ethanol vapor exposure (e.g., Finn and Crabbe 1999; Tanchuck et al. 2009; Terdal and Crabbe 1994) . All blood ethanol concentrations (BECs) were analyzed by headspace gas chromatography ) by the Finn laboratory, and ethanol vapor concentrations were adjusted to achieve BECs of 1.5-2.0 mg/mL. Upon removal from the inhalation chambers, separate groups of mice were euthanized at 8 h and at 48 h, but mice were not scored for HIC.
Blood and brain collection Trunk blood was collected, and plasma was separated and stored at −20°C. Plasma neurosteroid analysis by GC-MS utilized 300 μL samples. The neurosteroids examined included pregnenolone, DHEA, and the 3α,5α/3α,5β-GABA A R-active metabolites of progesterone, testosterone, DOC, and DHEA. Plasma CORT levels were measured in 5 μL samples with a commercially available double antibody radioimmunoassay kit (MP Biomedicals, Solon, OH), as recently described (Ford et al. 2013) . Dissected cortical (including prelimbic, cingulate, and overlying motor cortex) and entire hippocampal tissues were collected, rapidly frozen on dry ice, and stored at −20°C. Analysis of samples was singly determined.
Chemicals All extraction and derivatization solvents were chromatography grade (EMD Chemicals, Billerica, MA). Monodeuterated ethanol was obtained from Acros Organics (New Jersey), the derivatizing reagent heptafluorobutyric acid anhydride (HFAA) was obtained from Fluka (Sigma-Aldrich, St. Louis, MO), and the neurosteroids pregnenolone, pregnanolone, 3α,5β-THDOC, and 3α,5β-androstanediol were obtained from Steraloids (Newport, RI). All other native neurosteroid standards were synthesized by the late Dr. Robert Purdy. Similar to Snelling et al. (2014) , the internal standard (ISTD) was 17β-estradiol-2,4,16,16,17-d5 (CDN Isotopes, Pointe-Claire, Quebec, Canada). Ultra-pure water (double distilled; ddH 2 O) from a MilliQ system (Millipore Corporation, Bedford, MA) was used. Activated powdered charcoal (Darco-G-60) and Dextran (T-70) were obtained from Sigma-Aldrich.
Extraction of plasma steroids Solid phase extraction (SPE; Snelling et al. 2014 ) was used, with slight modification. Plasma (300 μL) was spiked with 10 ng estradiol-d5 (ISTD), loaded onto a preconditioned Strata-X-33u Polymeric Reversed Phase SPE column (Phenomenex, Torrance, CA), washed with 1 mL ddH 2 O and then with 1 mL 30% v/v methanol/ddH 2 O, and dried on a Waters vacuum manifold (Waters, Milford, MA). The dried cartridge was washed with 1 mL n-hexane, and dried for 15 min at 12 in Hg (inches of mercury, equal to 0.49 psi) of vacuum. Steroids were eluted from the SPE columns with two aliquots of 750 μL of acetonitrile, and the pooled eluate was dried on an Eppendorf Vacufuge for 90 min. Samples were derivatized or stored in a vacuum desiccator for up to 24 h.
Extraction of brain steroids
The extraction used wand homogenization followed by SPE, similar to the plasma steroids. Tissue (5-15 mg) was added to 1 mL ice cold ddH 2 O, spiked with 10 ng of estradiol-d5 (ISTD), and vortexed for 30 s. The spiked sample was wand homogenized with a Fisher Scientific Sonic Dismembrator Model 500 (Thermo Fisher, Waltham, MA) with a 45 s program of 500 ms on, 1000 ms off at 35% power. The sample was loaded on a preconditioned Strata-X-33u SPE column and treated identical to the extraction of plasma samples. After the pooled eluate was dried on an Eppendorf Vacufuge for 90 min, the sample was then derivatized or stored in a vacuum desiccator for up to 24 h.
Derivatization Extracted samples were solvated in acetonitrile (450 μL), HFAA (50 μL) was added, and samples were treated as described in Snelling et al. (2014) . The dried derivatized samples were resolvated in acetonitrile (10 μL) and transferred to a deactivated vial insert for immediate analysis.
Gas chromatography-mass spectrometry Samples and calibration curves (2 μL samples) were analyzed on an Agilent 7890A gas chromatograph coupled to an Agilent 5975C mass spectrometer detector (Agilent Technologies, Santa Clara, CA; Snelling et al. 2014) . Briefly, eluates were analyzed by the mass spectrometer in negative chemical ionization using methane (research grade 99.999%, Air Liquide, Houston, TX) as the reagent gas at a flow rate of 40%. The mass spectrometer chemical ionization source was set to 170°C and quadrupole mass filter temperature was set at 150°C. Selected ion monitoring was used, and data were collected for a minimum of two ions per analyte over five retention period groups (details in Snelling et al. 2014 ).
Calibration curves Calibration curves were formed by spiking 300 μL of ddH 2 O water with 0, 50, 100, 500, 1000, or 3000 pg of all ten analytes of interest and 10 ng of ISTD. The spiked reference standards were then extracted, derivatized, and analyzed by GC-MS. The ratio of the responses of the analyte divided by the response of the ISTD versus the concentration of the analyte was plotted. For each analyte, the response was an integration of the abundance counts collected by the MS detector horn for the target ion from baseline to baseline of the pertinent peak. No analytes co-eluted with other analytes or with the ISTD. Calibration curves were analyzed with linear regression, and unknown plasma or brain samples were interpolated against these regression parameters using their individual response ratios.
Method validation
We conducted additional validation experiments to verify accuracy, reliability, and reproducibility of the current GC-MS procedure for analysis of brain tissue. One milliliter of ddH 2 O was homogenized with 5-15 mg of brain tissue, then dextran-coated charcoal (250 mg charcoal/ 25 mg dextran) was added to the homogenate and vortexed for 60 s to strip the brain homogenate of endogenous steroids. The homogenate was centrifuged at 3500 rpm (~1900×g) for 30 min. The resultant supernatant was transferred to an Eppendorf vial and was spiked with both 10 ng of ISTD and one of four validation concentrations (0, 70, 300, and 700 pg) of all ten analytes of interest. All validation samples were analyzed as described above. To allow for measurement of coefficient of variation for intra-assay and inter-assay data, we independently assayed the four validation concentrations across four sets of steroid stripped brain homogenate samples. We also calculated matrix effects of the stripped brain homogenates by comparing a ratio of the response from the matrix (i.e., homogenate) samples versus the response from our calibration curve from the solvent only spiked samples to determine potential interference of proteins and lipids in the analyte quantification.
Data analysis Target ion peaks were integrated in ChemStation and interpolated using Prism6 (GraphPad Software Inc., San Diego, CA). Mean picogram per milliliter (plasma) or milligram (brain) of neurosteroid per extracted sample were calculated from the interpolated value and statistically analyzed with analysis of variance (ANOVA) for line and treatment (WSP and WSR studies) or treatment (DBA studies) effects. A similar strategy was used for the analysis of CORT levels. Significant interactions were followed up with post-hoc tests. Because we were predicting line differences, planned comparisons were conducted with or without the presence of a significant interaction. Effect size estimates (Cohen 1988) were calculated, with d = 0.2 considered a small effect, d = 0.5 a medium effect, and d = 0.8 a large effect. Pearson correlations analyzed relationships between ALLO and the other nine neurosteroids in cortex and hippocampus from air-versus ethanol-exposed mice at a time corresponding to peak WD (i.e., 8 h) to evaluate whether treatment differences in relationships would provide evidence for dysregulation in neurosteroid synthesis during WD. Significance was set at a p value of ≤0.05.
Results

GC-MS brain assay validation
We initially conducted a variety of control studies to validate the accuracy of our GC-MS approach to quantify neurosteroids in dissected brain tissues (Results in Supplemental Material). Briefly, the limits of quantification of our analytes were comparable to our assay in plasma per 2 μL aliquot, coefficients of variation were low, and there was an excellent linear response for all ten analytes of interest. The precision and accuracy of the control studies confirm the high level of confidence in the optimized assay.
Time course of changes in neurosteroids during ethanol WD in WSP-1 and WSR-1 mice Hippocampal and cortical neurosteroid levels at 8 h WD Plasma neurosteroid levels were analyzed and reported in a separate study (Snelling et al. 2014) . In the present study, BECs upon removal from the vapor chambers at 72 h were 1.5 ± 0.12 mg/mL (WSP-1, n = 13) and 1.6 ± 0.08 mg/mL (WSR-1, n = 11); these values were not significantly different from those in the earlier study [BEC = 1.6 ± 0.10 mg/mL (WSP-1) and 1.6 ± 0.16 mg/mL (WSR-1)]. Plasma CORT levels in the air-exposed mice were 16.87 ± 8.54 μg/dL (WSP-1; n = 13) and 17.46 ± 2.72 μg/dL (WSR-1; n = 15). Ethanol WD significantly increased plasma CORT levels in WSP-1 mice (135.36 ± 25.96 μg/dL, n = 11) and WSR-1 mice (80.93 ± 10.67 μg/dL, n = 10) [main effect of treatment: F(1,45) = 51.30, p < 0.001 and post-hoc tests: p < 0.001]. The significant interaction between line and treatment [F(1,45) = 4.69, p < 0.05] was due to the significantly greater WD-induced increase in plasma CORT levels in WSP-1 (703%) versus WSR-1 (363%) mice.
Cortical neurosteroid levels are depicted in Fig. 1 , and the two-way ANOVA results are summarized in Supplemental  Table 2 . In general, the results in cortex differed from our results in plasma (Snelling et al. 2014) , where similar WDinduced reductions in plasma levels of five neurosteroids, including ALLO, were observed in WSP-1 and WSR-1 mice. In the present study, ethanol WD significantly decreased eight cortical neurosteroid levels by 31-48% only in WSR-1 mice (Fig. 1) . In contrast, ethanol WD significantly increased 3α,5α-androstanediol levels (Fig. 1e ) in both WSP-1 and WSR-1 mice (19 and 34%, respectively), and increased levels of 3α,5α/3α,5β-androsterone by 122 and 68%, respectively (Fig. 1g, h ), only in WSP-1 mice.
Correlations revealed line and treatment differences in the relationships between cortical ALLO levels and levels of the other nine neurosteroids (Table 1 ). In WSP-1 air-exposed mice (Table 1 , top), ALLO levels were significantly positively correlated with levels of five neurosteroids, but significantly negatively correlated with 3α,5α-androstanediol levels. In contrast, only pregnanolone and pregnenolone levels remained significantly positively correlated with ALLO levels during ethanol WD. A different pattern of results was observed in WSR-1 mice (Table 1, middle) , with more significant correlations during WD than in controls (6 versus 4, respectively). There were some similarities with the results in WSP-1 mice; in both the air-and ethanol-exposed WSR-1 mice, ALLO levels were significantly positively correlated with pregnanolone and pregnenolone levels (similar to WSP-1 mice) and significantly negatively correlated with 3α,5α-androstanediol levels (similar to air-exposed WSP-1 mice).
Hippocampal neurosteroid levels are depicted in Fig. 2 , and the two-way ANOVA results are summarized in Supplemental Table 3 . Although no treatment effects reached statistical significance, there were some similarities in the pattern of the results that were found in the cortex in terms of percent (%) changes in neurosteroid levels during ethanol WD. Of the eight neurosteroids that were decreased significantly during WD in cortex in WSR-1 mice, six of them were decreased by 34-49% in hippocampus. In WSP-1 mice, the WDinduced increase in 3α,5α-androstanediol (Figs. 1e and 2e) and 3α,5β-androsterone (Figs. 1h and 2h) were similar in cortex and hippocampus.
There were line and treatment differences in the relationships between the levels of ALLO and other neurosteroids in hippocampus. In WSP-1 air-exposed mice, ALLO levels were significantly positively correlated with levels of the three 3α,5α-reduced neurosteroids and with 3α,5β-THDOC levels (Table 2, top). In contrast, during WD, ALLO levels were significantly positively correlated with levels of the three 3α,5β-reduced neurosteroids. In WSR-1 mice (Table 2 , middle), ALLO levels were significantly positively correlated with levels of six neurosteroids in the air controls, but there were only two significant positive correlations during ethanol WD. It is interesting that in both the air-and ethanol-exposed WSR-1 mice, ALLO levels were significantly positively correlated with 3α,5β-THDOC levels (similar to WSP-1 mice) and significantly positively correlated with 3α,5α-androsterone levels (similar to air-exposed WSP-1 mice).
Plasma, hippocampal, and cortical neurosteroid levels at 48 h WD Similar to the cohort of mice used for the 8 h WD studies, there was no line difference in BECs upon removal from the vapor chambers at 72 h between WSP-1 (1.79 ± 0.20 mg/mL, n = 8) and WSR-1 (1.75 ± 0.15 mg/ mL, n = 12) mice in the 48 h WD cohort. We were unable to analyze CORT levels in this cohort of mice, because of insufficient plasma remaining after the analysis of neurosteroid levels.
Plasma neurosteroids were considerably lower than in our prior work (Snelling et al. 2014) , and there were minimal changes at the 48 h WD time point versus values in the air controls (not shown). Depending on the neurosteroid, the values ranged from approximately 40 to 500 pg/mL, which are comparable to basal levels reported for C57 and DBA male mice (Porcu et al. 2010 ). The only WD-induced changes that were observed included a significant decrease in plasma pregnenolone levels by 8% in WSR-1 mice (p < 0.05) and a strong trend for an increase in plasma 3α,5α-androsterone levels of 9 and 14% in WSP-1 and WSR-1 mice, respectively [F(1,34) = 3.82, p < 0.06].
The majority of cortical neurosteroid levels were unaltered at 48 h WD ( Fig. 3 ; Supplemental Table 4 for ANOVA results). Only 3α,5β-androstanediol (Fig. 3f) was increased significantly in WSR-1 mice, which contrasted with the significant 40% decrease at 8 h WD (Fig. 1f) .
WD at 48 h produced a different pattern of results in hippocampal neurosteroid levels ( Fig. 4 ; ANOVAs in Supplemental Table 5 ) than seen at 8 h. Ethanol WD produced a similar significant decrease in 3α,5β-androstanediol levels (Fig. 4f) in the lines, while pregnanolone (Fig. 4d) and 3α,5β-androsterone (Fig. 4h ) levels were increased significantly in both WSP-1 and WSR-1 mice. In WSR-1 mice, there were opposite WD-induced changes in pregnenolone and DHEA levels (Fig. 4a, b) , and WD also produced line differences in the change in 3α,5α-androstanediol levels (Fig. 4e) .
Time course of changes in neurosteroids during ethanol WD in DBA mice Plasma, hippocampal, and cortical neurosteroid levels at 8 h WD BECs upon removal from the vapor chambers at 72 h were 1.49 ± 0.10 mg/mL (n = 18). Plasma CORT levels were measured in a subset of the animals [11.32 ± 2.37 μg/dL for air (n = 11); 72.64 ± 4.08 μg/dL for WD (n = 14)], Fig. 1 Line differences in the effect of peak chronic ethanol WD (i.e., 8 h) on cortical neurosteroid levels in male WSP-1 and WSR-1 mice. Mice were exposed to 72 h continuous ethanol vapor or air and euthanized at a time corresponding to peak WD in WSP-1 mice. Ethanol WD significantly decreased cortical levels of eight of the ten neurosteroids examined only in WSR-1 mice, with a significant increase in three cortical neurosteroid levels in WSP-1 mice. Values are shown as picogram/milligram and represent the mean ± SEM for the number of mice in parentheses. Also shown are the WD-induced percent changes (vs respective air control) that were >30%, including those that did not reach statistical significance. Note the different range of the y-axes across panels and that y-axes were kept constant for each pair of 3α,5α/3α,5β-neurosteroid metabolites. Slight differences in group size reflect cases where a statistical outlier (>2 standard deviation from the mean) was removed. *p < 0.05, **p < 0.01, ***p < 0.001 vs respective air control (planned comparison post-hoc tests; effect size range = 0.89-1.52); # p < 0.05 (main effect of treatment; effect size = 0.64) Table 1 Cortical neurosteroid correlations between levels of allopregnanolone (3α,5α-THP) and nine neurosteroids in WSP-1, WSR-1, and DBA mice at 8 h 3α,5α-diol 3α,5β-diol 3α,5α-one 3α,5β-one DHEA 3α,5β-THP PREG 3α,5α-THDOC 3α,5β-THDOC Pearson correlations were conducted between allopregnanolone and the other nine neurosteroids on the cortical neurosteroid data in mice at the 8 h time point for air-exposed mice (air) and for ethanol-exposed mice undergoing withdrawal (WD). Depicted are the correlations that were significant (in italic font) or were statistical trends (p ≤ 0.06)
ns not significant, 3α,5α/3α,5β-diol 3α,5α/3α,5β-androstanediol, 3α,5α/3α,5β-one 3α,5α/3α,5β-androsterone, DHEA dehydroepiandrosterone, 3α,5β-THP pregnanolone, PREG pregnenolone, 3α,5α/3α,5β-THDOC 3α,5α/3α,5β-tetrahydrodeoxycorticosterone representing a significant increase of 542% at the 8 h ethanol WD time point [F(1,23) = 145.95, p < 0.001].
As depicted in Fig. 5 , plasma levels of four neurosteroids were decreased significantly at 8 h WD in DBA mice. DHEA [F(1,32) = 13.51, p = 0.001], ALLO [F(1,32) = 38.0, p < 0.001], and 3α,5β-androstanediol [F(1,32) = 36.25, p < 0.001] levels were decreased by 20-21% during WD (Fig. 5b-f) , and 3α,5α-androstanediol [F(1,32) = 13.27, p = 0.001] levels were decreased by 13% during WD (Fig. 5e ).
There were minimal changes in cortical neurosteroid levels at 8 h WD (Fig. 6) . WD significantly increased 3α,5β-androstanediol levels by 30% [F(1,32) = 5.85, p < 0.05] Fig. 2 The effect of peak chronic ethanol WD (i.e., 8 h) on hippocampal neurosteroid levels in male WSP-1 and WSR-1 mice. Mice were treated as described in the legend to Fig. 1 . Depicted are the mean ± SEM picogram/ milligram for the number of mice in parentheses. Also shown are the WD-induced percent changes (vs respective air control) that were >30%. Note the different range of the y-axes across panels and that y-axes were kept constant for each pair of 3α,5α/3α,5β-neurosteroid metabolites. Slight differences in group size reflect cases where a statistical outlier (>2 standard deviation from the mean) was removed ( Fig. 6f ) and tended to decrease 3α,5α-androsterone levels by 24% [F(1,32) = 3.79, p = 0.06] (Fig. 6g ). There were no significant correlations between the levels of ALLO and other neurosteroids in the controls or during WD (Table 1, 
bottom).
Basal hippocampal neurosteroid levels were very similar to those in cortex (compare air controls in Figs. 6 and 7), and some of the WD-induced changes were similar in hippocampus and cortex. Hippocampal ALLO and 3α,5β-THDOC levels were significantly decreased by 7% [F(1,23) = 7.35, p = 0.01] and by 12% [F(1,23) = 11.47, p < 0.01] during WD (Fig. 7c, j) , but a similar 7% reduction in cortical ALLO levels and 15% reduction in cortical 3α,5β-THDOC levels during WD (Fig. 6c, j) did not reach significance. WD also significantly increased 3α,5β-androstanediol levels by 19% [F(1,23) = 6.49, p < 0.05] in hippocampus (Fig.  7f) , similar to what was observed in cortex (Fig. 6f) . In contrast, the WD-induced significant increase (20%) in hippocampal 3α,5α-androsterone [F(1,23) = 8.36, p < 0.01] (Fig. 7g) was opposite of that observed in cortex (Fig. 6g ). There were no significant correlations between neurosteroid levels in the air controls, but ALLO levels were significantly negatively correlated with 3α,5α-androsterone levels during WD (Table 2,  bottom) .
Plasma, hippocampal, and cortical neurosteroid levels at 48 h WD In this cohort of mice, BECs upon removal from the vapor chambers at 72 h were 1.84 ± 0.06 mg/mL (n = 12). Plasma CORT levels were 8.25 ± 2.08 μg/dL for air-exposed (n = 10) and 75.21 ± 5.70 μg/dL for 48 h WD (n = 12) mice, and they were similar to the levels measured at the 8 h WD time point. WD significantly increased plasma CORT by 812% at the 48 h time point [F(1,20) = 8.59, p < 0.01].
The quantification of plasma neurosteroids revealed significant divergent changes and a persistent suppression in three neurosteroid levels at 48 h WD ( Fig. 8 ; Supplemental Table 6 for ANOVA results). There was a sustained significant reduction in plasma DHEA, ALLO, and 3α,5β-androstanediol levels (compare Fig. 8b-f with Fig. 5b-f ). Plasma 3α,5α-THDOC also tended to be decreased at 48 h WD. In contrast, plasma pregnenolone, pregnanolone, 3α,5α-androstanediol, and 3α,5α-androsterone levels were significantly increased at 48 h WD.
Minimal changes were observed in cortical and hippocampal neurosteroid levels at the 48h WD time point (not shown), and the range in levels was very similar to those depicted in Figs. 6 and 7. The only significant WD-induced difference was in 3α,5α-THDOC levels, which were increased by 40% in the cortex [F(1,20) Table 2 Hippocampal neurosteroid correlations between levels of allopregnanolone (3α,5α-THP) and nine neurosteroids in WSP-1, WSR-1, and DBA mice at 8 h 3α,5α-diol 3α,5β-diol 3α,5α-one 3α,5β-one DHEA 3α,5β-THP PREG 3α,5α-THDOC 3α,5β-THDOC WSP-1; air n = 10-11 Pearson correlations were conducted between allopregnanolone and the other nine neurosteroids on the hippocampal neurosteroid data in mice at the 8 h time point for air-exposed mice (air) and for ethanol-exposed mice undergoing withdrawal (WD). Depicted are the correlations that were significant (in italic font) or were statistical trends (p < 0.06)
ns not significant, 3α,5α/3α,5β-diol 3α,5α/3α,5β-androstanediol, 3α,5α/3α,5β-one 3α,5α/3α,5β-androsterone, DHEA dehydroepiandrosterone, 3α,5β-THP pregnanolone, PREG pregnenolone, 3α,5α/3α,5β-THDOC 3α,5α/3α,5β-tetrahydrodeoxycorticosterone
Discussion
The present studies extended our recent report that simultaneously quantified neurosteroids in plasma of WSP-1 and WSR-1 male mice at 8 h WD to include analysis of neurosteroids in cortical and hippocampal tissue across the time course of WD-induced convulsive activity, and to compare the results to those obtained in DBA mice, another genetic animal model of high WD. Importantly, assay validation studies confirmed the high precision and accuracy of the optimized brain and plasma assays (see Supplemental Material), and significant differences were associated primarily with a large effect size (d > 0.8) or a medium effect size (d > 0.5) in a few cases. Thus, the present findings demonstrate that we are able to simultaneously identify and quantify ten neurosteroids in dissected brain tissues and that the power is sufficient to support the significant differences observed. Chronic ethanol exposure was comparable for all three genotypes in this and the previous studies, and ethanol WD produced a significant increase in plasma CORT across all three genotypes. However, the overall pattern of the neurosteroid results revealed significant genotype differences across the time course of WD. And, WD produced some divergent changes among neurosteroid levels (some increased and some decreased) and altered correlations between neurosteroid levels, indicating a broad and complex dysregulation in neurosteroid biosynthesis during WD. There also were differences in the WD-induced changes in plasma versus brain tissue, which fits with previous findings that basal neurosteroid levels in plasma do not simply reflect levels in cortex and hippocampus (Caruso et al. 2013) , and argues for independent regulation of neurosteroid synthesis in periphery and brain during WD.
The significant WD-induced increase in plasma CORT levels across all three genotypes is consistent with results in rodents (e.g., Janis et al. 1998; Finn et al. 2000; Koob 2008; Tanchuck et al. 2009 ) and in human alcoholics (e.g., Stalder et al. 2010; Stephens and Wand 2012; and references therein) during the early phase of WD. Earlier work also indicated that sensitivity to the proconvulsant effect of CORT differed in WSP versus WSR and in DBA versus C57 mice. Specifically, administration of CORT to naïve mice to mimic levels associated with WD significantly increased HIC scores and increased acute ethanol WD-induced HICs only in WSP and DBA mice (Roberts et al. 1991 (Roberts et al. , 1992 . Additionally, administration of aminoglutethimide (a glucocorticoid synthesis blocker to decrease CORT levels) decreased acute ethanol WD severity in WSP mice (Roberts et al. 1991) . Thus, genetic differences in the excitatory effects of glucocorticoids may influence WD severity.
WD-induced changes in plasma neurosteroids in DBA mice at 8 h were similar to those observed in WSP-1 and WSR-1 mice (Snelling et al. 2014) , with significant decreases in levels of DHEA, ALLO, and 3α,5α/3α,5β-androstanediol. Notably, three of the 8 h WD-induced changes in plasma neurosteroid levels persisted at the 48-h time point only in DBA mice. However, there also were opposite changes in levels of other GABA A R-active neurosteroids (see Fig. 8 ).
The divergent WD-induced changes in the 3α,5α-versus 3α,5β-derivatives of progesterone, testosterone, and DHEA were surprising, as they do not fit with a simple WD-induced effect on 5α-versus 5β-reductase activity on steroid precursors (for example), because an opposite pattern of changes was observed for the progesterone versus the testosterone and DHEA derived neurosteroids (compare Fig. 8 , panels c and d with panels e-h). Regardless, it is possible that the differing changes in neurosteroid levels at 48 h WD in DBA mice reflect an attempt to maintain a homeostatic balance in overall neurosteroid levels that is not disruptive to GABA A Rmediated inhibition and that corresponds to the termination of WD-induced changes in convulsive activity. Likewise, lack of significant WD-induced changes in neurosteroid levels at 48 h in WSP-1 and WSR-1 mice also can be interpreted as a return to baseline levels upon the termination of the acute phase of WD in mice (at 24-48 h in rodents; Heilig et al. 2010) . Collectively, the plasma results in WSP-1 and WSR-1 mice suggest that there was a transient suppression in the DHEA and testosterone pathway during WD and that the reduction in ALLO levels occurred at a point downstream from progesterone (discussed in Snelling et al. 2014) . In DBA mice, there was a persistent suppression in plasma DHEA levels, which may reflect an effect of ethanol WD on activity of P450c17, the enzyme responsible for the conversion of pregnenolone to 17α-hydroxypregnenolone and then to DHEA (Mellon and Vaudry 2001) . It is likely that the persistent suppression in plasma ALLO and 3α,5β-androstanediol levels occurred at a point downstream of progesterone and testosterone, respectively, given the opposite changes in pregnanolone and 3α,5α-androstanediol that were observed at the 48h time point. Notably, the finding that different modes of chronic ethanol exposure or consumption and WD produced a consistent reduction in plasma ALLO levels across rodent genotypes, in monkeys, and in humans (Beattie et al. 2017; Cagetti et al. 2004; Hill et al. 2005; Maldonado-Devincci et al. 2014; Romeo et al. 1996; Tanchuck et al. 2009 ) suggests that adrenal ALLO biosynthesis is suppressed during the acute phase of WD.
Absolute values of the neurosteroids during WD also should be considered when thinking about the potential functional implication of the consistent decreases in plasma ALLO levels during WD, as a decrease in levels below the physiologically relevant range would no longer potentiate GABA A R function. This is a distinct possibility for WSP-1 versus WSR-1 mice at 8 h WD (discussion in Snelling et al. 2014) . Additionally, earlier studies in human subjects found that individuals possessing a minor C-allele of the SRD5A1 gene, which encodes the enzyme 5α-reductase type 1, expressed both a higher ratio of dihydrotestosterone to testosterone (Ellis et al. 2005 ) and a decreased risk for alcohol dependence (Milivojevic et al. 2011 ), suggesting that a heightened level of 5α-reduced neurosteroid production may be protective against the development of dependence. In this context, a decline in enzyme function might be expected to decrease the biosynthesis of 5α-reduced neurosteroids and exacerbate the risk of dependence.
The pattern of changes in hippocampal and cortical neurosteroids varied across the time course of the acute WD phase in the three genotypes examined. It is interesting that the WSR-1 mice, which were selectively bred for low WDinduced convulsive activity, exhibited the most consistent decrease in cortical neurosteroid levels at 8 h WD; eight neurosteroids, including ALLO, were significantly decreased. This result is consistent with the decrease in ALLO immunoreactivity in the mPFC of low WD C57 mice at 8 h WD (Maldonado-Devincci et al. 2014) . However, the WDinduced decrease in ALLO immunoreactivity in the mPFC persisted at 72 h WD in the Maldonado-Devincci et al. (2014) study, whereas cortical ALLO levels were not significantly altered at 48 h WD in WSR-1 mice. These differences may be due to the differing duration and/or pattern of ethanol vapor exposure between the two studies (72 h continuous for WSR-1 mice; four bouts of repeated CIE for C57 mice). When comparing the cortical and hippocampal neurosteroid results during WD, similar % decreases in levels of six hippocampal neurosteroids to that seen in cortex also were observed at 8 h WD in WSR-1 mice, although the changes did not reach significance. ALLO immunoreactivity was significantly increased at 72 h WD only in the CA3 (Maldonado-Devincci et al. 2014 ), and we found that hippocampal pregnanolone (the 5β-stereoisomer of ALLO) levels were significantly increased at 48 h WD in WSR-1 mice. Additionally, divergent changes in hippocampal levels of other neurosteroids were observed (overall significant increases in three steroids, significant decreases in three steroids; Fig. 4 ), although we do not know if the WD-induced changes were limited to one or several hippocampal subregions. Collectively, the relatively consistent decrease in levels of cortical and some hippocampal neurosteroids at 8 h WD in WSR-1 mice may reduce GABA A R-neuronal inhibition in these brain regions, with a subsequent increase in glutamatergic output of the projection neurons. At 48 h WD, the opposite changes in levels of GABA A R-active neurosteroid levels may offset putative changes in GABA A R inhibition to maintain homeostasis at a time corresponding to the termination of the acute WD phase. Additionally, physiologically relevant ALLO levels exert effects on presynaptic GABA A Rs that are located on GABAergic or glutamatergic nerve terminals to increase GABA (e.g., Park et al. 2011; also reviewed in Herd et al. 2007) or glutamate release (e.g., Iwata et al. 2013) , respectively. While it is not known whether all GABA A R-active neurosteroids exert similar influences on presynaptic GABA and glutamate release, brain regional differences in the neuroanatomical localization of presynaptic GABA A Rs could produce mixed effects on CNS excitability.
Comparison of the hippocampal and cortical neurosteroid results in WSP-1 and DBA mice revealed that ethanol WD produced a different pattern of outcomes in these two genetic animal models of high ethanol WD. For instance, ALLO only was significantly decreased in hippocampus at 8 h WD in DBA mice, and significant changes in the levels of other hippocampal neurosteroids in DBA mice corresponded to an unchanged neurosteroid level in WSP-1 mice. Another interesting finding is that of the small proportion of cortical neurosteroids that were significantly changed, all were significantly increased in both WSP-1 mice and DBA mice (although different neurosteroids were increased in WSP-1 versus DBA mice). Because GABA levels can produce an inverse effect on steroidogenic enzyme activity in rodent brain (Do Rego et al. 2009) , it is possible that the increase in neurosteroid levels reflects a decrease in GABA release during ethanol WD. Consistent with this idea, preliminary evidence suggests that 72 h continuous ethanol vapor decreased presynaptic GABA release in dentate gyrus granule cells, measured by a decrease in frequency of miniature inhibitory post-synaptic currents in WSP-1 mice (Mohr, Richardson, Finn, and Rossi, unpublished) , although we do not know if similar WD-induced changes in GABA release occur in DBA mice. Thus, at least in WSP-1 mice, the increase in neurosteroid levels may reflect a homeostatic counter to decreases in GABA release. Similarly, 8 h ethanol WD also produced tolerance to the anticonvulsant effect of ALLO, and this decreased behavioral sensitivity to ALLO was accompanied by significantly reduced functional sensitivity of GABA A Rs to ALLO in WSP mice (Finn et al. 2006) , again compatible with increases in neurosteroid levels being a homeostatic counter to reduced sensitivity during WD, albeit clearly not adequate, given the heightened WD phenotype. Collectively, the results suggest that the decreased sensitivity of GABA A Rs to ALLO may exert a greater functional influence on GABA A R-mediated inhibition than the detected increases in neurosteroid levels in cortex and hippocampus and that, taken in conjunction with the concomitant decrease in presynaptic GABA release, would increase neuronal excitability in WSP-1 mice.
As mentioned above, hippocampal ALLO levels were decreased significantly in DBA mice at 8 h WD, as were 3α,5β-THDOC levels. As ALLO and THDOC are the most potent positive allosteric neurosteroid modulators of GABA A Rs, the functional implication of these WD-induced changes would be a decrease in GABA A R inhibition. In contrast, levels of 3α,5β-androstanediol and 3α,5α-androsterone were significantly increased. It is possible that these opposite changes in neurosteroid levels produce a net effect that does not functionally alter GABA A R inhibition at 8 h WD. However, other studies have determined that 8 h ethanol WD produced tolerance to the anticonvulsant efficacy of ALLO, suggestive of decreased sensitivity of GABA A Rs to ALLO during WD in DBA mice (Finn et al. 2000) . Notably, acute ethanol WD severity in male DBA mice is altered in a bidirectional manner Fig. 4 Ethanol WD (48 h) produces divergent changes in the pattern of hippocampal neurosteroid levels in male WSP-1 and WSR-1 mice. Mice were treated as described in the legend to Fig. 3 . While ethanol WD produced a similar significant decrease in 3α,5β-androstanediol levels in the lines, pregnanolone and 3α,5β-androsterone levels were increased significantly in both WSP-1 and WSR-1 mice. In WSR-1 mice, 48 h WD produced opposite significant changes in pregnenolone and DHEA levels, and WD also produced a line difference in the significant change in 3α,5α-androstanediol levels. Depicted are the mean ± SEM picogram/milligram for the number of mice in parentheses. Also shown are the WD-induced percent changes (vs respective air control) that were associated with significant differences. Note the different range of the y-axes across panels and that y-axes were kept constant for each pair of 3α,5α/3α,5β-neurosteroid metabolites. Slight differences in group size reflect cases where a statistical outlier (>2 standard deviation from the mean) was removed. *p < 0.05, **p < 0.01, ***p < 0.001 vs respective air control (planned comparison post-hoc tests; effect size = 1.23-2.28); by manipulation of GABA A R-active neurosteroid levels (Gililland and Finn 2007; Kaufman et al. 2010) ; i.e., adrenalectomy and gonadectomy (ADX/GDX) to reduce neurosteroids in the periphery increased acute ethanol WD severity, replacement with progesterone and DOC (GABA A R-active precursors) offset the ADX/GDX-induced increase in WD severity, and the Brescue^effect of progesterone and DOC was blocked with co-administration of finasteride (a 5α-reductase inhibitor that blocks metabolism of progesterone and DOC to GABA A R-active neurosteroids ALLO and 3α,5α-THDOC). Thus, the ADX/GDX results (Gililland and Finn 2007; Kaufman et al. 2010 ) provide evidence that endogenous neurosteroid levels can influence acute ethanol WD severity. Additional studies are necessary to Fig. 5 Decrease in plasma neurosteroid levels at 8 h WD in male DBA mice. Mice were exposed to 72 h continuous ethanol vapor or air and euthanized at a time corresponding to peak WD in DBA mice. Ethanol WD significantly decreased plasma levels of four neurosteroids, including allopregnanolone. Values are the mean ± SEM picogram/milliliter for the number of mice in parentheses (Group size is the same for all neurosteroids). Also shown are the WD-induced percent changes (vs air control) that were associated with significant differences. Note the different range of the y-axes across panels and that y-axes were kept constant for each pair of 3α,5α/3α,5β-neurosteroid metabolites. ***p ≤ 0.001 vs air control (effect size = 1.26-2.81) determine whether different GABA A R-active neurosteroid mechanisms influence ethanol WD severity in DBA versus WSP-1 mice, which would not be surprising given the multiple other differences between these genotypes. Importantly, genotypic characteristics of DBA mice arose fortuitously during inbreeding, while the genotypic characteristics of WSP and WSR mice were markedly influenced by direction selective pressures.
In conclusion, chronic ethanol exposure and WD dysregulated neurosteroid synthesis, with evidence for independent regulation of neurosteroid synthesis in the periphery and brain regions examined. The decrease in ALLO levels at 8 h WD in Fig. 6 Minimal changes in cortical neurosteroid levels at 8 h WD in male DBA mice. Mice were treated as described in the legend to Fig. 5 . Ethanol WD significantly increased 3α,5β-androstanediol levels and tended to decrease 3α,5α-androsterone levels. Values are shown as picogram/milligram and represent the mean ± SEM for the number of mice in parentheses (Group size is the same for all neurosteroids). Also shown are the WD-induced percent changes (vs air control) that were associated with significant differences or statistical trends. Note the different range of the yaxes across panels and that y-axes were kept constant for each pair of 3α,5α/3α,5β-neurosteroid metabolites. WSR-1 mice in plasma, cortex, and hippocampus, in DBA mice in plasma and hippocampus, and in WSP-1 mice in plasma (Snelling et al. 2014 ; this study) is consistent with data from other studies showing decreases in ALLO levels during the early phase of WD in rodents, monkeys, and humans (Beattie et al. 2017; Cagetti et al. 2004; Hill et al. 2005; Maldonado-Devincci et al. 2014; Romeo et al. 1996; Tanchuck et al. 2009 ). The results also add to evidence that neurosteroid levels are altered in several neuropsychiatric and neurological diseases and suggest that strategies to enhance aspects of neurosteroid synthesis may have therapeutic potential (Porcu et al. 2016) . Fig. 7 Divergent changes in hippocampal neurosteroid levels at 8 h WD in male DBA mice. Mice were treated as described in the legend to Fig. 5 . Ethanol WD significantly decreased ALLO and 3α,5β-THDOC levels and significantly increased 3α,5β-androstanediol and 3α,5α-androsterone levels. Depicted are the mean ± SEM picogram/ milligram for the number of mice in parentheses (Group size is the same for all neurosteroids). Also shown are the WD-induced percent changes (vs air control) that were associated with significant differences. Note the different range of the y-axes across panels and that y-axes were kept constant for each pair of 3α,5α/3α,5β-neurosteroid metabolites. *p < 0.05, **p ≤ 0.01 vs air control (effect size = 1.08-1.36)
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